Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Journal of Biological Response Modifiers|April 1, 1988
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2N S Rosenthal, J A Hank, P C Kohler, et al.
Medical and Pediatric Oncology|January 1, 1989
Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomasJ M Rozental, H I Robins, J Finlay, et al.
Cancer|June 15, 1989
"Eight-drugs-in-one-day" chemotherapy administered before and after radiotherapy to adult patients with malignant gliomasJ M Rozental, H I Robins, J Finlay, et al.
Experimental Hematology|May 1, 1986
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigensP M Sondel, J A Hank, M E Trigg, et al.
Cancer Research|December 1, 1989
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activityD Goldstein, J A Sosman, J A Hank, et al.
Cancer Research|April 1, 1988
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2J A Hank, P C Kohler, G Weil-Hillman, et al.
Journal of Clinical Microbiology|June 13, 2025
Accurate and reproducible whole-genome genotyping for bacterial genomic surveillance with Nanopore sequencing dataK Prior, K Becker, C Brandt, et al.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer Research|October 1, 1986
In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host diseaseP C Kohler, C Erickson, J L Finlay, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Pageof 19